JP2019529502A - アルツハイマー病及びパーキンソン病を処置するための組成物及び方法 - Google Patents

アルツハイマー病及びパーキンソン病を処置するための組成物及び方法 Download PDF

Info

Publication number
JP2019529502A
JP2019529502A JP2019517827A JP2019517827A JP2019529502A JP 2019529502 A JP2019529502 A JP 2019529502A JP 2019517827 A JP2019517827 A JP 2019517827A JP 2019517827 A JP2019517827 A JP 2019517827A JP 2019529502 A JP2019529502 A JP 2019529502A
Authority
JP
Japan
Prior art keywords
tablet
syn120
day
another embodiment
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019517827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529502A5 (enExample
Inventor
クリストファー ジー． サイレンタイン，
クリストファー ジー． サイレンタイン，
トーマス アール． メルフィット，
トーマス アール． メルフィット，
Original Assignee
バイオティー セラピーズ インコーポレイテッド
バイオティー セラピーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオティー セラピーズ インコーポレイテッド, バイオティー セラピーズ インコーポレイテッド filed Critical バイオティー セラピーズ インコーポレイテッド
Publication of JP2019529502A publication Critical patent/JP2019529502A/ja
Publication of JP2019529502A5 publication Critical patent/JP2019529502A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019517827A 2016-09-30 2017-09-29 アルツハイマー病及びパーキンソン病を処置するための組成物及び方法 Pending JP2019529502A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402357P 2016-09-30 2016-09-30
US62/402,357 2016-09-30
PCT/US2017/054473 WO2018064559A1 (en) 2016-09-30 2017-09-29 Compositions and methods for treating alzheimer's disease and parkinson's disease

Publications (2)

Publication Number Publication Date
JP2019529502A true JP2019529502A (ja) 2019-10-17
JP2019529502A5 JP2019529502A5 (enExample) 2020-11-12

Family

ID=61756894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517827A Pending JP2019529502A (ja) 2016-09-30 2017-09-29 アルツハイマー病及びパーキンソン病を処置するための組成物及び方法

Country Status (10)

Country Link
US (3) US10314798B2 (enExample)
EP (1) EP3518914A4 (enExample)
JP (1) JP2019529502A (enExample)
AR (1) AR109760A1 (enExample)
AU (2) AU2017337053B2 (enExample)
CA (1) CA3037059A1 (enExample)
IL (1) IL265656A (enExample)
MX (2) MX387961B (enExample)
TW (1) TWI753952B (enExample)
WO (1) WO2018064559A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023500904A (ja) * 2019-11-04 2023-01-11 シンクルス・ファーマ・ホールディング・アクチエボラグ Ｘ８４２の経口製剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017337053B2 (en) 2016-09-30 2021-09-02 Biotie Therapies, Inc. Compositions and methods for treating alzheimer's disease and parkinson's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060069094A1 (en) * 2004-09-30 2006-03-30 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
US20060167255A1 (en) * 2004-12-21 2006-07-27 Roche Palo Alto Llc Tetralin and indane derivatives and uses thereof
US20080015256A1 (en) * 2006-06-20 2008-01-17 Roche Palo Alto Llc Tetralin and indane derivatives and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368083A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
FR2974102B1 (fr) * 2011-04-13 2014-08-22 Rhodia Operations Composition polyamide stabilisee
US20150320706A1 (en) * 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
AU2017337053B2 (en) 2016-09-30 2021-09-02 Biotie Therapies, Inc. Compositions and methods for treating alzheimer's disease and parkinson's disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060069094A1 (en) * 2004-09-30 2006-03-30 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
US20060167255A1 (en) * 2004-12-21 2006-07-27 Roche Palo Alto Llc Tetralin and indane derivatives and uses thereof
US20080293751A1 (en) * 2004-12-21 2008-11-27 Roche Palo Alto Llc Tetralin and indane derivatives and uses thereof
US20120088837A1 (en) * 2004-12-21 2012-04-12 Roche Palo Alto Llc Tetralin and indane derivatives and uses thereof
US20080015256A1 (en) * 2006-06-20 2008-01-17 Roche Palo Alto Llc Tetralin and indane derivatives and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 20, JPN6021038083, 2010, pages 3436 - 3440, ISSN: 0004602537 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023500904A (ja) * 2019-11-04 2023-01-11 シンクルス・ファーマ・ホールディング・アクチエボラグ Ｘ８４２の経口製剤
JP7681819B2 (ja) 2019-11-04 2025-05-23 シンクルス・ファーマ・ホールディング・アクチエボラグ・パブリーク Ｘ８４２の経口製剤

Also Published As

Publication number Publication date
EP3518914A4 (en) 2020-06-10
MX2021014093A (es) 2021-12-10
US20190142771A1 (en) 2019-05-16
US20210177783A1 (en) 2021-06-17
IL265656A (en) 2019-05-30
AU2021277698A1 (en) 2021-12-23
AR109760A1 (es) 2019-01-23
WO2018064559A1 (en) 2018-04-05
CA3037059A1 (en) 2018-04-05
AU2017337053B2 (en) 2021-09-02
TW201813638A (zh) 2018-04-16
MX387961B (es) 2025-03-19
US10314798B2 (en) 2019-06-11
AU2017337053A1 (en) 2019-04-04
US10973784B2 (en) 2021-04-13
TWI753952B (zh) 2022-02-01
EP3518914A1 (en) 2019-08-07
MX2019003720A (es) 2019-09-19
US20180092868A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
DK2605757T3 (en) Nalbuphine-based formulations and applications thereof
KR102116087B1 (ko) 리카르바제핀 아세테이트를 포함하는 경구 투여형
CN110944638A (zh) 尼拉帕尼组合物
JP7586523B2 (ja) 改善されたブロモクリプチン製剤
JP2009542647A (ja) メマンチン医薬組成物
JP2025169294A (ja) カルバメート化合物を含む経口用医薬組成物及びその製造方法
TWI418370B (zh) 溶出安定性製劑
JP6019116B2 (ja) （トリメトキシフェニルアミノ）ピリミジニル製剤
US20210177783A1 (en) Compositions and methods for treating alzheimer&#39;s disease and parkinson&#39;s disease
US20230026232A1 (en) Ahr inhibitors and uses thereof
WO2012144592A1 (ja) 固形医薬組成物
JP6731136B2 (ja) 医薬製剤
JP6669937B2 (ja) ５−ｈｔ６拮抗薬の医薬組成物
JP2011153135A (ja) タルチレリン製剤およびタルチレリン製剤の溶出性維持方法
CN102088961A (zh) 依普罗沙坦组合物
US20110160213A1 (en) Pharmaceutical compositions for the treatment of inflammatory and allergic disorders
JP2024520860A (ja) 固体剤形のメラトニン製剤
HK1155364A (en) Eprosartan compositions
HK1161089A (en) Solid dosage forms of bendamustine
HK1161089B (en) Solid dosage forms of bendamustine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220602